BR0317774A - Uso de rimexolona no tratamento de olho seco - Google Patents

Uso de rimexolona no tratamento de olho seco

Info

Publication number
BR0317774A
BR0317774A BR0317774-2A BR0317774A BR0317774A BR 0317774 A BR0317774 A BR 0317774A BR 0317774 A BR0317774 A BR 0317774A BR 0317774 A BR0317774 A BR 0317774A
Authority
BR
Brazil
Prior art keywords
dry eye
rimexolone
methods
eye
drug
Prior art date
Application number
BR0317774-2A
Other languages
English (en)
Inventor
John M Yanni
Daniel A Gamache
Steven T Miller
Ernesto J Castillo
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0317774A publication Critical patent/BR0317774A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE RIMEXOLONA NO TRATAMENTO DE OLHO SECO". A presente invenção refere-se a uma composições oftálmicas tópicas e métodos para o tratamento de olho seco são descritos. As composições e métodos da invenção são baseados na descoberta de que as propriedades seletivas de superfície ocular do glicocorticóide rimexolona tornam este agente antiinflamatório particularmente bem adequado para o tratamento de olho seco. Como resultado da capacidade limitada de rimexolona para penetrar a córnea, uma porção elevada da droga permanece na superfície do olho, que é o local primário das condições inflamatórias associadas com olho seco. Isto permite uma concentração muito baixa da droga a ser utilizada, o que por sua vez reduz o potencial com relação a elevações de pressão intraocular e formação de catarata.
BR0317774-2A 2002-12-24 2003-12-18 Uso de rimexolona no tratamento de olho seco BR0317774A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43625502P 2002-12-24 2002-12-24
PCT/US2003/040374 WO2004058273A1 (en) 2002-12-24 2003-12-18 Use of rimexolone in the treatment of dry eye

Publications (1)

Publication Number Publication Date
BR0317774A true BR0317774A (pt) 2005-11-22

Family

ID=32682365

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317774-2A BR0317774A (pt) 2002-12-24 2003-12-18 Uso de rimexolona no tratamento de olho seco

Country Status (24)

Country Link
US (3) US20040132704A1 (pt)
EP (1) EP1575597B1 (pt)
JP (1) JP2006513213A (pt)
KR (2) KR100889170B1 (pt)
CN (1) CN100388919C (pt)
AR (1) AR042790A1 (pt)
AT (1) ATE419856T1 (pt)
AU (1) AU2003299696B2 (pt)
BR (1) BR0317774A (pt)
CA (1) CA2507375C (pt)
CY (1) CY1108862T1 (pt)
DE (1) DE60325770D1 (pt)
DK (1) DK1575597T3 (pt)
ES (1) ES2316867T3 (pt)
HK (1) HK1076248A1 (pt)
MX (1) MXPA05006985A (pt)
PL (1) PL378877A1 (pt)
PT (1) PT1575597E (pt)
RU (1) RU2330668C2 (pt)
SI (1) SI1575597T1 (pt)
TW (1) TWI335819B (pt)
UY (1) UY28126A1 (pt)
WO (1) WO2004058273A1 (pt)
ZA (1) ZA200503975B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7779039B2 (en) 2004-04-02 2010-08-17 Salesforce.Com, Inc. Custom entities and fields in a multi-tenant database system
WO2006031848A2 (en) * 2004-09-15 2006-03-23 Ivax Corporation Corticosteroid topical dispersion with low content of surfactant
CN101258483B (zh) 2005-09-09 2015-08-12 易享信息技术（上海）有限公司 用于在多租户数据库环境中导出、发布、浏览和安装随需应用的系统及其方法
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
US8138156B2 (en) * 2006-10-18 2012-03-20 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
US8629099B2 (en) * 2008-03-25 2014-01-14 Bausch & Lomb Incorporated Ophthalmic compositions comprising a dipeptide
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100087550A1 (en) * 2008-10-06 2010-04-08 Zora Marlowe Formulations with a Tertiary Amine Oxide
ES2487542T3 (es) * 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公司 作为jak抑制剂的化合物
AU2010256652B2 (en) * 2009-06-05 2015-11-26 Allergan, Inc. Artificial tears and therapeutic uses
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8324171B1 (en) 2012-02-06 2012-12-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US8664180B2 (en) 2012-02-06 2014-03-04 Bausch & Lomb Incorporated Ophthalmic compositions containing diglycine
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
HUE057262T2 (hu) 2013-03-06 2022-04-28 Incyte Holdings Corp Eljárás és köztitermékek JAK inhibitor elõállítására
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
RU2559580C1 (ru) * 2014-03-18 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) Препарат для лечения синдрома "сухого глаза"
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN106420797A (zh) * 2016-12-06 2017-02-22 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合及其制备方法
CN106581035A (zh) * 2016-12-06 2017-04-26 郑州郑先医药科技有限公司 一种治疗干眼病的西药组合物
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
KR102269835B1 (ko) 2019-10-08 2021-06-29 한국전력공사 펜형 케이블 식별장치 및 케이블 식별 시스템
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20240166971A1 (en) * 2022-10-26 2024-05-23 Bausch + Lomb Ireland Limited Contact lens treating solution

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
JPS63203620A (ja) * 1985-10-30 1988-08-23 アルコン　ラボラトリ−ズ　インコ−ポレイテツド 眼科用の抗炎症性組成物
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
JPH06153607A (ja) * 1992-11-30 1994-06-03 Kinsaku Kida 農耕用作業車と農耕作業部との連結装置
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
EP0984782A2 (en) * 1997-06-04 2000-03-15 Akzo Nobel N.V. Use of anti-inflammatory steroids for the treatment of chronic inflammatory intestinal diseases
CA2379605C (en) * 1999-09-24 2007-06-26 Alcon, Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone

Also Published As

Publication number Publication date
KR100889170B1 (ko) 2009-03-16
KR20090018222A (ko) 2009-02-19
CA2507375C (en) 2009-11-24
US20080096852A1 (en) 2008-04-24
AU2003299696A1 (en) 2004-07-22
US20040132704A1 (en) 2004-07-08
CN1732008A (zh) 2006-02-08
CA2507375A1 (en) 2004-07-15
MXPA05006985A (es) 2005-08-16
AU2003299696B2 (en) 2009-08-13
RU2330668C2 (ru) 2008-08-10
KR20050086937A (ko) 2005-08-30
EP1575597A1 (en) 2005-09-21
UY28126A1 (es) 2004-06-30
CN100388919C (zh) 2008-05-21
ZA200503975B (en) 2006-12-27
EP1575597B1 (en) 2009-01-07
ES2316867T3 (es) 2009-04-16
TWI335819B (en) 2011-01-11
HK1076248A1 (en) 2006-01-13
SI1575597T1 (sl) 2009-04-30
TW200418492A (en) 2004-10-01
AR042790A1 (es) 2005-07-06
US20060058277A1 (en) 2006-03-16
CY1108862T1 (el) 2014-07-02
PL378877A1 (pl) 2006-05-29
DE60325770D1 (de) 2009-02-26
JP2006513213A (ja) 2006-04-20
RU2005123388A (ru) 2006-01-20
ATE419856T1 (de) 2009-01-15
PT1575597E (pt) 2009-02-02
DK1575597T3 (da) 2009-03-16
WO2004058273A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
BR0317033A (pt) Vitreólise farmacológica
BRPI0406880A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de inibidores de anidrase carbÈnicos
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ATE418325T1 (de) Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon- acetonid und hyaluronsäure
BRPI0509332A (pt) implantes oculares biodegradáveis com caracterìsticas de liberação a longo prazo
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BR112022015579A2 (pt) Composições para tratamento de doenças oculares
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
TW200511996A (en) The use of steroids to treat persons suffering from ocular disorders
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
CY1111384T1 (el) Διαμορφωση των επιπεδων εκφρασης toy trpv
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
CA3167959A1 (en) Prodrug for the treatment of disease and injury of oxidative stress
ATE144139T1 (de) Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
CY1121044T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια οφθαλμικων διαταραχων
RU2750902C1 (ru) Способ проведения кросслинкинга роговичного коллагена и одновременной имплантации интрастромальных роговичных сегментов на парном глазу у пациентов с разными стадиями кератоконуса
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
HUP0300566A2 (hu) Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.